低分子肝素和普通肝素在急性冠脉综合征中使用的对比性研究

Comparative study on Nadroparin Calcium and Unfractionated Heparin in acute coronary syndrome in the safety of using

目的:对低分子肝素和普通肝素在急性冠脉综合征中的疗效及安全性进行评价。方法:对本组84例急性冠脉综合征患者采用随机双盲法分为A组(普通肝素)36例,B组(低分子肝素)48例。A组将肝素钠针6250U加入极化液500ml中静滴,每分钟40滴,每日1次;B组低分子肝素5000U皮下注射,Q12h,每日测凝血时间、血小板计数及纤维蛋白原。疗程均为10d。结果:A组总有效率为91.6%,心电图改善率为83.0%;B组总有效率为93.8%,心电图改善率为87.0%;两组无显著性差异(χ2=1.02,P>0.05)。结论:低分子肝素和普通肝素在治疗量下均安全可靠,但普通肝素在降低医疗总费用上优于低分子肝素。

Objective： To evaluation of Nadroparin Calcium and Unfractionated Heparin in treatment of acute coronary syndrome safety and efficacy. Methods： In 84 eases of acute coronary syndrome patients randomized double-blind points Unfractionated Heparin （group A） 36 cases, Nadroparin Calcium （group B） 48 cases. Unfractionated Heparin 6 250 U would join in the static drops liquid 500 ml polarization for group A, every minute, every day 1 of 40 drops, Nadroparin Calcium 5 000 U subcutaneous injection for group B, Q12h, clotting times daily, platelet count and fibrinogen were determined. A course for 10 days. Results： The total effective rate of group A was 91.6%, ECG improvement rate was 83.0%. The total effective rate of group B was 93.8%, ECG improvement rate was 87.0%.The two groups had no significant difference （Х^2=1.02,P〉0.05）.Conclusion： Nadroparin Calcium and Unfractionated Heparin in treatment of both safe and reliable, but Unfraetionated Heparin in reducing the total cost of health care is superior to Nadroparin Calcium.